Analyst Ratings for [NVTA] Invitae Corporation

7/5/23	Resumed	Underweight	X
NVTA Invitae JP Morgan
5/15/23	Downgrades	Mkt Perform Underperform	X
NVTA Invitae Raymond James
1/31/23	Downgrades	Neutral Sell	X
NVTA Invitae Goldman
$2
8/25/22	Initiated	Underperform	X
NVTA Invitae Credit Suisse
$1
8/10/22	Downgrades	Neutral Underweight	X
NVTA Invitae JP Morgan
7/26/22	Downgrades	Outperform Mkt Perform	X
NVTA Invitae Cowen
$8 $2.50
7/20/22	Downgrades	Buy Neutral	X
NVTA Invitae Ladenburg Thalmann
7/19/22	Downgrades	Outperform Mkt Perform	X
NVTA Invitae SVB Leerink
7/19/22	Downgrades	Buy Hold	X
NVTA Invitae The Benchmark Company
6/3/22	Initiated	Underweight	X
NVTA Invitae Piper Sandler
$2.50
6/15/21	Initiated	Outperform	X
NVTA Invitae Raymond James
$37
6/3/21	Initiated	Neutral	X
NVTA Invitae Goldman
$33
5/25/21	Initiated	Equal Weight	X
NVTA Invitae Wells Fargo
$30
4/5/21	Upgrades	Perform Outperform	X
NVTA Invitae Oppenheimer
$48
2/18/21	Upgrades	Neutral Buy	X
NVTA Invitae Ladenburg Thalmann
$46.50 $58
2/1/21	Downgrades	Outperform Perform	X
NVTA Invitae Oppenheimer
8/7/19	Reiterated	Buy	X
NVTA Invitae The Benchmark Company
$26 $28
3/4/19	Initiated	Buy	X
NVTA Invitae Chardan Capital Markets
$29
12/19/18	Initiated	Outperform	X
NVTA Invitae Oppenheimer
11/20/18	Resumed	Buy	X
NVTA Invitae The Benchmark Company
$17
2/13/18	Reiterated	Buy	X
NVTA Invitae The Benchmark Company
$11 $10

NVTA Invitae Corporation

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.